News Releases

Mallinckrodt To Present At Barclays Global Healthcare Conference

STAINES-UPON-THAMES, United Kingdom, Feb. 15, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, March 14, 2018, at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel, 1601 Collins Ave. in Miami Beach, Fla.

Matthew Harbaugh, Executive Vice President and Chief Financial Officer, and Steven Romano, M.D., Executive Vice President and Chief Scientific Officer, will represent the company in a fireside chat at 10:15 a.m. Eastern.   

Individuals who cannot attend the meeting in person can find webcast information at: A replay will also be available following the meeting.

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.


Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO

Daniel J. Speciale, CPA
Director, Investor Relations

Rhonda Sciarra
Senior Communications Manager

Meredith Fischer
Chief Public Affairs Officer

Mallinckrodt, the "M" brandmark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2018 02/18


Cision View original content with multimedia:

SOURCE Mallinckrodt Pharmaceuticals